Drug Profile
AZ 40140
Alternative Names: SB 418790Latest Information Update: 10 Jul 2023
Price :
$50
*
At a glance
- Originator Asahi Kasei
- Developer GSK
- Class
- Mechanism of Action Beta 3 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Diabetes mellitus; Obesity
Most Recent Events
- 05 Nov 2002 Discontinued - Phase-I for Diabetes mellitus in USA (unspecified route)
- 05 Nov 2002 Discontinued - Phase-I for Obesity in USA (unspecified route)
- 04 Jul 2002 Phase -I clinical trials in Diabetes mellitus in USA (unspecified route)